Leerink Partners analyst David Risinger maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on January 24 and set a price ...

Lots of people are on cheaper compounded weight-loss drugs that mimic brands like Ozempic, Wegovy, and Zepbound. They're ...

For its most recently reported quarter (Q3 of 2024), Hims & Hers generated $401.6 million in revenue. That resulted in a free ...

If your weight loss goals have taken a backward step, this simple device might be all you need to get back on track and shed ...

But, no matter what direction the general market takes, some stocks could stand out, potentially in 2025, and most ...

Vertex's lineup will look transformed in five years, and the company should continue performing well beyond that time. It's ...

Tirzepatide works by targeting multiple pathways ... from unauthorized retailers or online marketplaces. By choosing to buy directly from the official website, consumers can have peace of mind ...

It's the start of a new year, and that makes now the perfect time to load up on stocks that could boost your portfolio in ...

Eli Lilly (NYSE: LLY) sells many products across treatment areas, from immunology to neuroscience. The company sells ...

In clinical trials, tirzepatide (the active ingredient in both Mounjaro and ... profits (based on analyst estimates), Eli ...

Lilly makes tirzepatide, sold under the name Zepbound for weight loss and Mounjaro for type 2 diabetes. These products have quickly become blockbusters, bringing in billions of dollars in revenue.